What Is the Significance of Variant Histology in Urothelial Carcinoma?

Niyati Lobo, Shahrokh F. Shariat, Charles Chuanhai Guo, Mario A. Fernandez, Wassim Kassouf, Ananya Choudhury, Jianjun Gao, Stephen Williams, Matthew D. Galsky, John A. Taylor, Morgan Roupret, Ashish M. Kamat

    Research output: Contribution to journalReview article

    Abstract

    Context: Urothelial carcinoma can exhibit a wide range of variant morphologies. Many variants present diagnostic challenges and carry clinical implications that inform prognosis and treatment decisions. Objective: To provide an overview of the diagnostic, therapeutic, and prognostic significance of histological variants of urothelial carcinoma. Evidence acquisition: A PubMed/MEDLINE-based literature search was conducted using the key terms “urothelial carcinoma”, “variant histology”, “nested”, “micropapillary”, “microcystic”, “sarcomatoid”, “squamous differentiation”, “glandular differentiation”, “clear cell”, “plasmacytoid”, “lymphoepithelioma-like carcinoma”, “squamous cell carcinoma”, “small cell carcinoma”, “adenocarcinoma”, “radiotherapy”, “neoadjuvant chemotherapy”, and “adjuvant chemotherapy”. Evidence synthesis: The incidence of variant histology is increasing due to improved recognition. Nonetheless, diagnosis can pose challenges due to sampling limitations and interobserver variability. Although associated with advanced disease at presentation, survival outcomes for most variants do not differ significantly compared with pure urothelial carcinoma of the same stage. Controversy exists regarding optimal management due to the low quality of available evidence. For most cases, radical cystectomy with pelvic lymph node dissection (with neoadjuvant chemotherapy when appropriate) represents the standard of care. Small cell carcinoma and lymphoepithelioma-like carcinoma appear to be particularly chemosensitive. Conclusions: Accurate identification of variant histological subtypes is an important part of risk stratification, as these variants exhibit aggressive biological behaviour. Variant histology tumours are associated with advanced disease at presentation, which must be considered when counselling patients regarding survival outcomes. Optimal management remains to be defined but in most cases; neoadjuvant chemotherapy and radical cystectomy with pelvic lymph node dissection remains the mainstay of treatment. Patient summary: It is important to recognise histological variants of urothelial carcinoma as they indicate aggressive disease. When compared with patients with pure urothelial carcinoma of the same disease stage, survival does not appear to be significantly worse. In most cases, patients with invasive variant histology should be treated with neoadjuvant chemotherapy and radical cystectomy. Take Home Messages Accurate identification of variant histology is important as it exhibits aggressive biological behaviour and affects treatment. Although associated with advanced disease at presentation, with appropriate treatment, survival outcomes are not significantly different compared with pure urothelial carcinoma of the same stage.

    Original languageEnglish (US)
    JournalEuropean Urology Focus
    DOIs
    StateAccepted/In press - Jan 1 2019

    Fingerprint

    Histology
    Carcinoma
    Cystectomy
    Drug Therapy
    Small Cell Carcinoma
    Survival
    Lymph Node Excision
    Observer Variation
    Therapeutics
    Adjuvant Chemotherapy
    Standard of Care
    PubMed
    MEDLINE
    Counseling
    Cell Differentiation
    Squamous Cell Carcinoma
    Adenocarcinoma
    Radiotherapy
    Incidence
    Neoplasms

    Keywords

    • Adenocarcinoma
    • Bladder cancer
    • Clear cell urothelial carcinoma
    • Lymphoepithelioma-like carcinoma
    • Microcystic urothelial carcinoma
    • Micropapillary urothelial carcinoma
    • Nested urothelial carcinoma
    • Plasmacytoid urothelial carcinoma
    • Sarcomatoid urothelial carcinoma
    • Small cell carcinoma
    • Squamous cell carcinoma
    • Variant histology

    ASJC Scopus subject areas

    • Urology

    Cite this

    Lobo, N., Shariat, S. F., Guo, C. C., Fernandez, M. A., Kassouf, W., Choudhury, A., ... Kamat, A. M. (Accepted/In press). What Is the Significance of Variant Histology in Urothelial Carcinoma? European Urology Focus. https://doi.org/10.1016/j.euf.2019.09.003

    What Is the Significance of Variant Histology in Urothelial Carcinoma? / Lobo, Niyati; Shariat, Shahrokh F.; Guo, Charles Chuanhai; Fernandez, Mario A.; Kassouf, Wassim; Choudhury, Ananya; Gao, Jianjun; Williams, Stephen; Galsky, Matthew D.; Taylor, John A.; Roupret, Morgan; Kamat, Ashish M.

    In: European Urology Focus, 01.01.2019.

    Research output: Contribution to journalReview article

    Lobo, N, Shariat, SF, Guo, CC, Fernandez, MA, Kassouf, W, Choudhury, A, Gao, J, Williams, S, Galsky, MD, Taylor, JA, Roupret, M & Kamat, AM 2019, 'What Is the Significance of Variant Histology in Urothelial Carcinoma?', European Urology Focus. https://doi.org/10.1016/j.euf.2019.09.003
    Lobo, Niyati ; Shariat, Shahrokh F. ; Guo, Charles Chuanhai ; Fernandez, Mario A. ; Kassouf, Wassim ; Choudhury, Ananya ; Gao, Jianjun ; Williams, Stephen ; Galsky, Matthew D. ; Taylor, John A. ; Roupret, Morgan ; Kamat, Ashish M. / What Is the Significance of Variant Histology in Urothelial Carcinoma?. In: European Urology Focus. 2019.
    @article{9368a09c0b774bea80ddcbc2a5d48826,
    title = "What Is the Significance of Variant Histology in Urothelial Carcinoma?",
    abstract = "Context: Urothelial carcinoma can exhibit a wide range of variant morphologies. Many variants present diagnostic challenges and carry clinical implications that inform prognosis and treatment decisions. Objective: To provide an overview of the diagnostic, therapeutic, and prognostic significance of histological variants of urothelial carcinoma. Evidence acquisition: A PubMed/MEDLINE-based literature search was conducted using the key terms “urothelial carcinoma”, “variant histology”, “nested”, “micropapillary”, “microcystic”, “sarcomatoid”, “squamous differentiation”, “glandular differentiation”, “clear cell”, “plasmacytoid”, “lymphoepithelioma-like carcinoma”, “squamous cell carcinoma”, “small cell carcinoma”, “adenocarcinoma”, “radiotherapy”, “neoadjuvant chemotherapy”, and “adjuvant chemotherapy”. Evidence synthesis: The incidence of variant histology is increasing due to improved recognition. Nonetheless, diagnosis can pose challenges due to sampling limitations and interobserver variability. Although associated with advanced disease at presentation, survival outcomes for most variants do not differ significantly compared with pure urothelial carcinoma of the same stage. Controversy exists regarding optimal management due to the low quality of available evidence. For most cases, radical cystectomy with pelvic lymph node dissection (with neoadjuvant chemotherapy when appropriate) represents the standard of care. Small cell carcinoma and lymphoepithelioma-like carcinoma appear to be particularly chemosensitive. Conclusions: Accurate identification of variant histological subtypes is an important part of risk stratification, as these variants exhibit aggressive biological behaviour. Variant histology tumours are associated with advanced disease at presentation, which must be considered when counselling patients regarding survival outcomes. Optimal management remains to be defined but in most cases; neoadjuvant chemotherapy and radical cystectomy with pelvic lymph node dissection remains the mainstay of treatment. Patient summary: It is important to recognise histological variants of urothelial carcinoma as they indicate aggressive disease. When compared with patients with pure urothelial carcinoma of the same disease stage, survival does not appear to be significantly worse. In most cases, patients with invasive variant histology should be treated with neoadjuvant chemotherapy and radical cystectomy. Take Home Messages Accurate identification of variant histology is important as it exhibits aggressive biological behaviour and affects treatment. Although associated with advanced disease at presentation, with appropriate treatment, survival outcomes are not significantly different compared with pure urothelial carcinoma of the same stage.",
    keywords = "Adenocarcinoma, Bladder cancer, Clear cell urothelial carcinoma, Lymphoepithelioma-like carcinoma, Microcystic urothelial carcinoma, Micropapillary urothelial carcinoma, Nested urothelial carcinoma, Plasmacytoid urothelial carcinoma, Sarcomatoid urothelial carcinoma, Small cell carcinoma, Squamous cell carcinoma, Variant histology",
    author = "Niyati Lobo and Shariat, {Shahrokh F.} and Guo, {Charles Chuanhai} and Fernandez, {Mario A.} and Wassim Kassouf and Ananya Choudhury and Jianjun Gao and Stephen Williams and Galsky, {Matthew D.} and Taylor, {John A.} and Morgan Roupret and Kamat, {Ashish M.}",
    year = "2019",
    month = "1",
    day = "1",
    doi = "10.1016/j.euf.2019.09.003",
    language = "English (US)",
    journal = "European Urology Focus",
    issn = "2405-4569",
    publisher = "Elsevier BV",

    }

    TY - JOUR

    T1 - What Is the Significance of Variant Histology in Urothelial Carcinoma?

    AU - Lobo, Niyati

    AU - Shariat, Shahrokh F.

    AU - Guo, Charles Chuanhai

    AU - Fernandez, Mario A.

    AU - Kassouf, Wassim

    AU - Choudhury, Ananya

    AU - Gao, Jianjun

    AU - Williams, Stephen

    AU - Galsky, Matthew D.

    AU - Taylor, John A.

    AU - Roupret, Morgan

    AU - Kamat, Ashish M.

    PY - 2019/1/1

    Y1 - 2019/1/1

    N2 - Context: Urothelial carcinoma can exhibit a wide range of variant morphologies. Many variants present diagnostic challenges and carry clinical implications that inform prognosis and treatment decisions. Objective: To provide an overview of the diagnostic, therapeutic, and prognostic significance of histological variants of urothelial carcinoma. Evidence acquisition: A PubMed/MEDLINE-based literature search was conducted using the key terms “urothelial carcinoma”, “variant histology”, “nested”, “micropapillary”, “microcystic”, “sarcomatoid”, “squamous differentiation”, “glandular differentiation”, “clear cell”, “plasmacytoid”, “lymphoepithelioma-like carcinoma”, “squamous cell carcinoma”, “small cell carcinoma”, “adenocarcinoma”, “radiotherapy”, “neoadjuvant chemotherapy”, and “adjuvant chemotherapy”. Evidence synthesis: The incidence of variant histology is increasing due to improved recognition. Nonetheless, diagnosis can pose challenges due to sampling limitations and interobserver variability. Although associated with advanced disease at presentation, survival outcomes for most variants do not differ significantly compared with pure urothelial carcinoma of the same stage. Controversy exists regarding optimal management due to the low quality of available evidence. For most cases, radical cystectomy with pelvic lymph node dissection (with neoadjuvant chemotherapy when appropriate) represents the standard of care. Small cell carcinoma and lymphoepithelioma-like carcinoma appear to be particularly chemosensitive. Conclusions: Accurate identification of variant histological subtypes is an important part of risk stratification, as these variants exhibit aggressive biological behaviour. Variant histology tumours are associated with advanced disease at presentation, which must be considered when counselling patients regarding survival outcomes. Optimal management remains to be defined but in most cases; neoadjuvant chemotherapy and radical cystectomy with pelvic lymph node dissection remains the mainstay of treatment. Patient summary: It is important to recognise histological variants of urothelial carcinoma as they indicate aggressive disease. When compared with patients with pure urothelial carcinoma of the same disease stage, survival does not appear to be significantly worse. In most cases, patients with invasive variant histology should be treated with neoadjuvant chemotherapy and radical cystectomy. Take Home Messages Accurate identification of variant histology is important as it exhibits aggressive biological behaviour and affects treatment. Although associated with advanced disease at presentation, with appropriate treatment, survival outcomes are not significantly different compared with pure urothelial carcinoma of the same stage.

    AB - Context: Urothelial carcinoma can exhibit a wide range of variant morphologies. Many variants present diagnostic challenges and carry clinical implications that inform prognosis and treatment decisions. Objective: To provide an overview of the diagnostic, therapeutic, and prognostic significance of histological variants of urothelial carcinoma. Evidence acquisition: A PubMed/MEDLINE-based literature search was conducted using the key terms “urothelial carcinoma”, “variant histology”, “nested”, “micropapillary”, “microcystic”, “sarcomatoid”, “squamous differentiation”, “glandular differentiation”, “clear cell”, “plasmacytoid”, “lymphoepithelioma-like carcinoma”, “squamous cell carcinoma”, “small cell carcinoma”, “adenocarcinoma”, “radiotherapy”, “neoadjuvant chemotherapy”, and “adjuvant chemotherapy”. Evidence synthesis: The incidence of variant histology is increasing due to improved recognition. Nonetheless, diagnosis can pose challenges due to sampling limitations and interobserver variability. Although associated with advanced disease at presentation, survival outcomes for most variants do not differ significantly compared with pure urothelial carcinoma of the same stage. Controversy exists regarding optimal management due to the low quality of available evidence. For most cases, radical cystectomy with pelvic lymph node dissection (with neoadjuvant chemotherapy when appropriate) represents the standard of care. Small cell carcinoma and lymphoepithelioma-like carcinoma appear to be particularly chemosensitive. Conclusions: Accurate identification of variant histological subtypes is an important part of risk stratification, as these variants exhibit aggressive biological behaviour. Variant histology tumours are associated with advanced disease at presentation, which must be considered when counselling patients regarding survival outcomes. Optimal management remains to be defined but in most cases; neoadjuvant chemotherapy and radical cystectomy with pelvic lymph node dissection remains the mainstay of treatment. Patient summary: It is important to recognise histological variants of urothelial carcinoma as they indicate aggressive disease. When compared with patients with pure urothelial carcinoma of the same disease stage, survival does not appear to be significantly worse. In most cases, patients with invasive variant histology should be treated with neoadjuvant chemotherapy and radical cystectomy. Take Home Messages Accurate identification of variant histology is important as it exhibits aggressive biological behaviour and affects treatment. Although associated with advanced disease at presentation, with appropriate treatment, survival outcomes are not significantly different compared with pure urothelial carcinoma of the same stage.

    KW - Adenocarcinoma

    KW - Bladder cancer

    KW - Clear cell urothelial carcinoma

    KW - Lymphoepithelioma-like carcinoma

    KW - Microcystic urothelial carcinoma

    KW - Micropapillary urothelial carcinoma

    KW - Nested urothelial carcinoma

    KW - Plasmacytoid urothelial carcinoma

    KW - Sarcomatoid urothelial carcinoma

    KW - Small cell carcinoma

    KW - Squamous cell carcinoma

    KW - Variant histology

    UR - http://www.scopus.com/inward/record.url?scp=85072175132&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=85072175132&partnerID=8YFLogxK

    U2 - 10.1016/j.euf.2019.09.003

    DO - 10.1016/j.euf.2019.09.003

    M3 - Review article

    JO - European Urology Focus

    JF - European Urology Focus

    SN - 2405-4569

    ER -